Therapy Areas: Respiratory
Cantargia gets French approval for CESTAFOUR clinical study
10 September 2021 -

Swedish biotechnology company Cantargia AB (STO:CANTA) reported on Friday it has received approval from the regulatory authority and ethics committee in France for the phase I/II clinical study CESTAFOUR.

This study broadens the clinical development for nadunolimab (CAN04) to include biliary tract cancer (BTC), colorectal cancer (CRC) and late-stage non-small lung cancer (NSCLC) and will evaluate CAN04 in combination with standard of care chemotherapy.

Planned to take place at approximately 20 clinical centres in Europe, the study will include up to 165 patients. The first patient is anticipated to be enrolled in September/October 2021.

CAN04, an interleukin-1 receptor accessory protein (IL1RAP)-binding antibody, is currently being investigated in multiple clinical trials in combination with various chemotherapy regimens, primarily in NSCLC and pancreatic cancer.



Related Headlines